AGL 40.21 Increased By ▲ 0.18 (0.45%)
AIRLINK 127.64 Decreased By ▼ -0.06 (-0.05%)
BOP 6.67 Increased By ▲ 0.06 (0.91%)
CNERGY 4.45 Decreased By ▼ -0.15 (-3.26%)
DCL 8.73 Decreased By ▼ -0.06 (-0.68%)
DFML 41.16 Decreased By ▼ -0.42 (-1.01%)
DGKC 86.11 Increased By ▲ 0.32 (0.37%)
FCCL 32.56 Increased By ▲ 0.07 (0.22%)
FFBL 64.38 Increased By ▲ 0.35 (0.55%)
FFL 11.61 Increased By ▲ 1.06 (10.05%)
HUBC 112.46 Increased By ▲ 1.69 (1.53%)
HUMNL 14.81 Decreased By ▼ -0.26 (-1.73%)
KEL 5.04 Increased By ▲ 0.16 (3.28%)
KOSM 7.36 Decreased By ▼ -0.09 (-1.21%)
MLCF 40.33 Decreased By ▼ -0.19 (-0.47%)
NBP 61.08 Increased By ▲ 0.03 (0.05%)
OGDC 194.18 Decreased By ▼ -0.69 (-0.35%)
PAEL 26.91 Decreased By ▼ -0.60 (-2.18%)
PIBTL 7.28 Decreased By ▼ -0.53 (-6.79%)
PPL 152.68 Increased By ▲ 0.15 (0.1%)
PRL 26.22 Decreased By ▼ -0.36 (-1.35%)
PTC 16.14 Decreased By ▼ -0.12 (-0.74%)
SEARL 85.70 Increased By ▲ 1.56 (1.85%)
TELE 7.67 Decreased By ▼ -0.29 (-3.64%)
TOMCL 36.47 Decreased By ▼ -0.13 (-0.36%)
TPLP 8.79 Increased By ▲ 0.13 (1.5%)
TREET 16.84 Decreased By ▼ -0.82 (-4.64%)
TRG 62.74 Increased By ▲ 4.12 (7.03%)
UNITY 28.20 Increased By ▲ 1.34 (4.99%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 10,086 Increased By 85.5 (0.85%)
BR30 31,170 Increased By 168.1 (0.54%)
KSE100 94,764 Increased By 571.8 (0.61%)
KSE30 29,410 Increased By 209 (0.72%)

China's government announced Sunday that a vaccine for Severe Acute Respiratory Syndrome (SARS) had emerged from the first phase clinical test as both safe and effective, state press reported. Xinhua news agency quoted Wang Xiaofang, a senior official with the Ministry of Science and Technology, as saying that 36 volunteers, who had been injected with the vaccine 56 days earlier, had not reported any abnormal physical reactions and that antibodies were found in 24.
Yin Weidong, director of the research program, was quoted as saying the test was strictly secured and that his team had already set technical standards for manufacturing the vaccine.
Xinhua quoted Lin Jiangtao, a professor at the Sino-Japanese Friendship Hospital who co-ordinated the clinical test, as saying the test carried out since May covered 18 men and 18 women aged 21 to 40.
The tests were carried out after success with animals, Xinhua said.
However the drug will not be ready for commercial use until the completion of the second and third phase tests, Xinhua said, without giving details of what they would entail nor when they would be completed.
Late last month a Beijing newspaper had said the tests were expected to be completed by January.
Sars killed almost 800 people, mostly in Hong Kong and China, in a world-wide outbreak that infected more than 8,000 by the end of last year.

Copyright Agence France-Presse, 2004

Comments

Comments are closed.